(NASDAQ: ARDX) Ardelyx's forecast annual revenue growth rate of 15.34% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 84.56%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.65%.
Ardelyx's revenue in 2025 is $386,146,000.On average, 6 Wall Street analysts forecast ARDX's revenue for 2025 to be $90,841,127,826, with the lowest ARDX revenue forecast at $87,862,339,089, and the highest ARDX revenue forecast at $92,826,585,346. On average, 6 Wall Street analysts forecast ARDX's revenue for 2026 to be $109,568,867,321, with the lowest ARDX revenue forecast at $94,954,463,717, and the highest ARDX revenue forecast at $130,275,316,817.
In 2027, ARDX is forecast to generate $142,791,964,903 in revenue, with the lowest revenue forecast at $112,811,291,272 and the highest revenue forecast at $183,725,308,067.